research report · VYGR

Voyager Therapeutics, Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 5, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 5, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Mixed

material evidence both ways

financial resilience

Fragile

needs money within two years that it has not secured

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Voyager is buying time by shrinking, not by building a revenue base. Third-quarter (Q3) revenue was $4.0M, about three-quarters of it Novartis paying for research Voyager performs on its behalf, after income from past upfront payments ran out. Operating cash use fell to $19.7M from $31.0M a year earlier. That makes management's runway "into the second quarter of 2028" on $132.1M of cash and securities credible, but it covers only 18 to 21 months from September 30, and the company says it needs substantial additional funding. The case turns on two near, small events: tau imaging data from VY7523, guided for Q4 2026, and first dosing of VY1706, which had not begun as of the 10-Q.

what changed this quarter

  • Q3 revenue was $4.0M vs $13.4M a year earlier. Operating expenses were $30.4M vs $44.0M, and the net loss was $24.7M vs $27.9M.
  • Q3 operating cash use was $19.7M vs $31.0M a year earlier. Cash and securities were $132.1M at September 30 vs $148.8M at June 30.
  • Runway guidance is "into the second quarter of 2028", against "into 2028" in the annual report.
  • A September 2026 reduction in force cost $1.4M. On October 20, Robin Swartz became President; she is expected to succeed CEO Alfred Sandrock after VY1706 safety data anticipated in Q1 2027.
  • VY7523's last patient visit was in October, with data guided for Q4 2026. VY1706 patients are being screened.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Revenue has shrunk to partner reimbursement; the upfront money is used up
  • Cost cuts have aligned cash use with guidance, but not with two years
  • The tests are near and small, and the VY1706 timetable has loosened

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what VYGR files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on VYGR say?” Add Viridis to Claude, or to ChatGPT.